Scinai Immunotherapeutics SCNI
NASDAQ SCNI
$0.62 +0.01 (+0.97%)
As of: Oct 22, 2026 · 3:31 PM EDT

Scinai Immunotherapeutics (SCNI) Return on Equity [ROE] (2021 - 2026)

Updated

Scinai Immunotherapeutics (SCNI) reported Return on Equity [ROE] of -71.31% for Q2 2026, up 14.21 percentage points from the prior quarter.

Analysis

Scinai Immunotherapeutics (SCNI) Return on Equity [ROE] (2021 - 2026) Analysis & Trends

For FY2025, Scinai Immunotherapeutics posted Return on Equity [ROE] of -121.25%, down 298.62 percentage points from FY2024.

  • By year, Return on Equity [ROE] came in at 177.37% in FY2024.
  • The Q2 2026 figure ranks as the highest quarterly Return on Equity [ROE] since Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,170.42 Bn 1,139.01 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 648.22 Bn 568.08 Bn 17.30 Bn 19.33%
3 AbbVie 504.43 Bn 477.54 Bn 12.70 Bn -
4 Merck 369.14 Bn 323.52 Bn 12.21 Bn 7.21%
5 Novartis Ag 303.29 Bn 267.28 Bn 11.24 Bn 31.52%
6 Astrazeneca 268.21 Bn 241.90 Bn 12.86 Bn 21.39%
7 Amgen 242.56 Bn 197.96 Bn 7.24 Bn 83.75%
8 Gilead Sciences 194.91 Bn 169.11 Bn 6.22 Bn -18.38%
9 Pfizer 173.28 Bn 119.92 Bn 10.94 Bn 4.97%
10 Scinai Immunotherapeutics 143,757.65 -8.12 Mn -1.25 Mn -71.31%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -71.31%
Mar 31, 2026 -85.51%
Dec 31, 2024 37.15%
Sep 30, 2024 32.88%
Dec 31, 2022 -5,362.09%
Sep 30, 2022 403.76%
Jun 30, 2022 -957.20%
Mar 31, 2022 -319.69%
Dec 31, 2021 -240.97%
Sep 30, 2021 -304.57%
API Access

Scinai Immunotherapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SCNI&period=max&api_key=YOUR_API_KEY